List of Welireg drug patents

Welireg is owned by Merck Sharp Dohme.

Welireg contains Belzutifan.

Welireg has a total of 2 drug patents out of which 0 drug patents have expired.

Welireg was authorised for market use on 13 August, 2021.

Welireg is available in tablet;oral dosage forms.

Welireg can be used as treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.

Drug patent challenges can be filed against Welireg from August, 2025.

The generics of Welireg are possible to be released after 05 September, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 13, 2026
Orphan Drug Exclusivity (ODE) Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

NCE-1 date: August, 2025

Market Authorisation Date: 13 August, 2021

Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in